No Detail Found!

Relapse rate of Vivax Malaria with different regimens of antirelapse treatment in Iran: a field evaluation.

Author(s)
Masoud Salehi Department of Tropical and Infectious Disease, Faculty of Medicine, Zahedan University of Medical Sciences and Health Services, Iran
Fatemeh Rakhshani Faculty of Public Health, Zahedan University of Medical Sciences and Health Services, Iran
Abstract
In this study shorter duration of antirelapse therapy was compared to that of 8 weeks regimen. In 1998 and 1999 antirelapse therapy of vivax in Sistan and Baluchestan province in southeast of Iran was done with different regimens according to manpower and executive facilities. A cohort study was compared clinically and parasitological relapse of vivax malaria in 200 patients with one-week therapy, 200 patients with 2 weeks, 800 patients with 4 weeks and 500 patients with 8 weeks therapy by primaquine. Relapse rates of vivax malaria by each regimen were 23.8, 13.2, 5.4 and 4.6%, respectively. Relative risk of relapse in comparison with 8 weeks regimen was 5.2, 2.9 and 1.2, respectively. Number Need to Harm (NNH) was 5, 12 and 125. Interval of the first relapse varied between 6 to 52 weeks with the mean of 28.8 weeks (CI 95%: 24.2-33.1). The relapse rate was not different between men and women. The relapse rate by 4 and 8 weeks regimes were low and there was not significant difference of relapse rate in 4 and 8 weeks regimes. It is recommended to use 4 weeks therapy instead of 8 weeks therapy in special situations.
Publication Details
Page(s) 125-129
DOI DOI not available
Published Journal: Journal of Medical Science, Volume: 5, Issue: 2, Year: 2005

Request the full text from PASTIC

0

Citations

0

Downloads

26

Views